Cancer immunity

Poorly immunogenic cancer cells evade host immunity and grow even in the presence of an intact immune system, but the complex mechanisms regulating tumor immunogenicity have not been understood. We have discovered an unexpected and exciting role of the Hippo intracellular pathway in suppressing immunogenicity.

Although the recent development of cancer immunotherapy raises high hope for cancer treatment, a major limitation of the current immune checkpoint blockade is the low response rate. Our observations suggest that the Hippo pathway is a new target for cancer immunotherapy since improving immunogenicity of cancer cells by inhibiting Hippo pathway is a strategy complementary to the current immunotherapy of relieving immune suppression. We aim to provide scientific bases to target the Hippo intracellular pathway for cancer immunotherapy. 

熊本大学 大学院生命科学研究部

総合医薬科学部門 代謝・循環医学分野



〒860-8556 熊本市中央区本荘1-1-1

(受付) TEL: 096-373-5173

FAX: 096-373-5313

E-MAIL: moroishi [at]

Department of Molecular and Medical Pharmacology

Faculty of Life Sciences, Kumamoto University


1-1-1 Honjo, Chuo-ku, Kumamoto,

Kumamoto 860-8556, JAPAN

(Desk) TEL: +81-96-373-5173

FAX: +81-96-373-5313
E-MAIL: moroishi [at]